Welcome to our dedicated page for Bolt Biotherapeutics SEC filings (Ticker: BOLT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, sourced in real time from the U.S. Securities and Exchange Commission’s EDGAR system. As a clinical-stage biopharmaceutical company developing immunotherapies for cancer, Bolt Biotherapeutics uses its SEC filings to report financial results, material corporate events, and updates on its research and development activities.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q to understand the company’s research and development spending, collaboration revenue from its partnerships, and detailed risk factors related to advancing product candidates such as BDC-3042 and BDC-4182. These filings also describe the Boltbody ISAC platform, the status of clinical and preclinical programs, and the company’s cash position and operating runway as disclosed in its financial statements.
Current reports on Form 8-K provide timely information about specific events, such as announcements of quarterly financial results, restructuring plans that include workforce reductions, and updates on ongoing clinical studies. For example, Bolt Biotherapeutics has used Form 8-K to furnish press releases describing changes to the BDC-4182 Phase 1 protocol and the expected timing of initial clinical data, as well as to outline cost-reduction measures intended to preserve cash.
Through this page, users can also access insider transaction reports on Form 4 and other relevant filings, when available, to monitor equity transactions by officers and directors. Stock Titan’s interface is designed to pair these documents with AI-powered summaries that explain key points in accessible language, helping readers quickly interpret complex disclosures without replacing the underlying source documents. By reviewing Bolt Biotherapeutics’ SEC filings alongside news and market data, investors can form a more complete picture of the company’s financial condition, pipeline progress, and regulatory communications.
Bolt Biotherapeutics (BOLT) insider activity: the company’s Senior VP, Finance and PAO reported two transactions. On June 6, 2025, the officer purchased 125 shares of common stock at $5.492, acquired under the Employee Stock Purchase Plan. On October 22, 2025, the officer received 23,000 restricted stock units for no consideration; each RSU represents one share upon settlement and will vest in full on September 15, 2026, assuming continued employment. Following these transactions, direct beneficial ownership stands at 23,943 shares.
Bolt Biotherapeutics (BOLT) reported an insider equity award. The Chief Operating Officer received 30,000 restricted stock units for no consideration on 10/22/2025. Each RSU represents the right to receive one share of common stock at settlement.
The award will vest in full on September 15, 2026, assuming continued employment through that date. Following the reported transaction, the officer beneficially owned 38,918 shares of common stock, held directly.
Bolt Biotherapeutics (BOLT) disclosed insider equity activity by its President, CEO and CFO, William P. Quinn. On 10/22/2025, he acquired 40,000 restricted stock units (RSUs) for $0. Each RSU represents one share of common stock at settlement, and the award vests in full on September 15, 2026, assuming continued employment.
Earlier, on 06/06/2025, Quinn purchased 125 shares of common stock at $5.492 per share under the company’s Employee Stock Purchase Plan, which is exempt under Rule 16b-3(c). After the reported transactions, he beneficially owned 42,188 shares directly.
Bolt Biotherapeutics is implementing a major restructuring to cut operating expenses and preserve cash. The company will reduce its workforce by about 20 employees, representing roughly 50% of its staff, and expects pre-tax charges of $1.5 million to $2.0 million for severance, benefits, and related costs. These charges are expected to be recorded in the fourth quarter of 2025, with the reduction-in-force completed by the end of 2025.
The company also provided an update on its ongoing Phase 1 dose escalation study of BDC-4182, a next-generation Boltbody ISAC targeting claudin 18.2. A strong immune response was observed at initial dose levels, and the protocol is being modified to allow step-up dosing, which is supported by preclinical data. Bolt now expects to report initial clinical data in the third quarter of 2026 and states that the workforce reduction is intended to conserve capital and extend its cash runway into 2027.
Bolt Biotherapeutics (BOLT) disclosure shows Tang Capital affiliates and Kevin Tang collectively report beneficial ownership of 166,879 shares of common stock, representing 8.7% of the class on a post-reverse-split basis. The holders report shared voting and dispositive power over these shares and no sole voting or dispositive power. The percentage is calculated using the issuer's disclosed outstanding share count adjusted for a one-for-twenty reverse stock split. The filing includes a certification that the securities were not acquired to change or influence control of the issuer.
FAQ
What is the current stock price of Bolt Biotherapeutics (BOLT)?
What is the market cap of Bolt Biotherapeutics (BOLT)?
